Cyclo Therapeutics announces positive safety profile of its drug Trappsol Cyclo
Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Tag: HPBCD
Ginkgo terpenoid against COVID-19
Due to the reported high ability of virulence of COVID_19 in recent months, several studies have been conducted to discover
Solubilization and stabilization of beta-acids from hop extract by HPBCD
Hops are the flowers (also called seed cones or strobiles) of the hop plant Humulus lupulus. They are used primarily
Fast-dissolving antioxidant curcumin/cyclodextrin inclusion complex electrospun nanofibrous webs
Curcumin/Hydroxypropyl-beta-Cyclodextrin (HP-β-CD) and Curcumin/Hydroxypropyl-gamma-Cyclodextrin (HP-γ-CD) inclusion complex nanofibrous webs were produced using electrospinning technique for the purpose of orally fast-dissolving
The role of Roquette’s KLEPTOSE® HPbCD in the fight against coronavirus
Roquette has recently identified that its KLEPTOSE® hydroxypropyl beta-cyclodextrins (HPβCD) product, a functional excipient and a specialty active pharmaceutical ingredient (API),
Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Antibacterial activity of lavender oil encapsulated in HPBCD
Since ancient times, lavender has served as a natural remedy in herbal and aromatherapy. People used to fill pillows with
Monoterpene-cyclodextrin complexes against bacteria
Monoterpenes have antimicrobial properties but are associated with strong smells and flavors that limit their use in foods; therefore, strategies
Role of cyclodextrins in the extraction and bioremediation of soils co-contaminated by organic pollutants and potentially toxic elements
Pollution of soils by persistent organic pollutants and potentially toxic elements (PTEs) is currently a significant concern worldwide. In many
HPBCD is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease
Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin